GLP-1 drugs like Ozempic are famous for curbing appetite — but a growing body of research suggests they also quiet cravings for things like alcohol and nicotine, and scientists are zeroing in on where in the brain that happens.
Writing about the science, University of Otago researcher Robert Munn highlights the lateral septum, a brain region packed with GLP-1 receptors that acts as a control point “between thinking about a reward and feeling compelled to pursue it.” It takes in information from the hippocampus about where and when you are, and adds context about “what is good in this place” before signaling dopamine-producing reward centers.
The evidence so far
Human studies have found GLP-1 medicines reduce alcohol consumption, and preclinical animal work shows lower use of cocaine, amphetamines, opioids and nicotine. Activating GLP-1 signaling directly in the lateral septum has been shown to reduce food intake in mice, with similar effects on alcohol — hinting that this hub may be a shared switch for many kinds of craving.
Why it matters
If GLP-1 drugs work partly by turning down a general “craving” circuit, that could open new approaches to treating addiction, not just obesity. “These drugs are changing how we think about the brain’s reward system,” Munn writes. The idea is still being worked out — much of the direct brain evidence is from animals — but it reframes these blockbuster medicines as tools that may reach well beyond the stomach.